RxSight, Inc. Reports First Quarter 2025 Financial Results

About this update from Rxsight, Inc.

[{"type":"image","alt":"RxSight, Inc.","displaySize":"","headline":null,"caption":"RxSight, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RlZbsYuiF8.V1Nc6BC4.Lw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4","width":300,"height":92}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025.","length":292,"tagName":"p"},{"type":"text","content":"Key Quarterly Highlights ","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting:","length":123,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of March 31, 2025, which represents a 43% expansion compared to the installed base of 732 LDDs at end of the first quarter of 2024; and","length":227,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":370,"olType":false}]},{"val":[{"type":"text","content":"The company reiterated its 2025 full-year revenue, gross margin and operating expense guidance.","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":588,"olType":false},{"type":"text","content":"“The exceptional clinical value delivered by our Light Adjustable Lens continues to drive significant enthusiasm among cataract surgeons,” said Ron Kurtz, Chief Executive Officer and President of RxSight. “The excitement and engagement we observed at the recent ASCRS meeting further reinforces our conviction that customization and post-operative adjustability are shaping the future of premium c...

More updates from Rxsight, Inc.